Grifols has faced renewed pressure from bearish funds after a period of leadership in its stock price. On Thursday, the multinational involved in hemoderivatives experienced a sharp drop, nearly 35 percent, followed by a partial recovery close to 15 percent on Friday. The aim behind these positions, including actions identified by Gotham City through claims about accounting practices intended to portray a lighter debt load, appears to be a bet against the stock while locking in profits later.
